Patent · US Active

Methods and compositions using Kloto-FGF23 fusion polypeptides

US8932589B2 · kind B2 · utility

37Cited by
7References
17Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 12, 2013
Grant dateJan 13, 2015
Priority date—
Expiry dateMay 22, 2033

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/32
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.